Phreesia Stock Plummets After Mixed Q4 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PHR?
Source: Fool
- Earnings Report Disappointment: Phreesia's Q4 2026 earnings report revealed a revenue of $127.1 million, surpassing expectations, yet the earnings per share of $0.02 fell significantly short of the anticipated $0.06, resulting in a 27.5% stock drop in early trading.
- Sales Growth Highlight: Despite the earnings miss, Phreesia achieved a 16% year-over-year sales increase and reported profitability for both the quarter and the full year at $0.04 per share, indicating some resilience in the market.
- Free Cash Flow Performance: The company generated a positive free cash flow of $28.5 million for the quarter and $54.4 million for the year, reflecting a solid cash position after accounting for capital expenditures and software costs, despite the earnings challenges.
- Cautious Future Outlook: Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million from a previous range of $545 million to $559 million, highlighting uncertainty regarding spending commitments from pharmaceutical clients, although it still anticipates a 7% growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.410
Low
24.00
Averages
29.09
High
35.00
Current: 11.410
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PHREESIA Q4 ADJUSTED EBITDA REACHES USD 29.4 MILLION, BEATING IBES ESTIMATE OF USD 28.1 MILLION
Financial Comparison: PHREESIA reported a Q4 adjusted EBITDA of USD 29.4 million, indicating strong financial performance.
Industry Benchmark: In contrast, the estimate for IBESE's adjusted EBITDA stands at USD 28.1 million, highlighting a competitive landscape.
See More
PHREESIA REPORTS Q4 NET INCOME OF USD 1.295 MILLION
- Company Overview: PHR EESIA reported a net income of USD 1.295 million for Q4.
- Financial Performance: The financial results indicate a positive performance in the fourth quarter.
See More
PHREESIA REPORTS RESULTS FOR FOURTH QUARTER OF FISCAL YEAR 2026
- Fiscal Results Announcement: PHR EESIA has announced its fiscal results for the fourth quarter of 2026.
- Performance Overview: The results provide insights into the financial performance and economic standing of the organization during this period.
See More
Phreesia Set to Announce Q4 Earnings on March 30
- Earnings Announcement Schedule: Phreesia (PHR) is set to announce its Q4 earnings on March 30 after market close, with a consensus EPS estimate of $0.32, reflecting a substantial year-over-year increase of 390.9%, indicating a significant improvement in the company's profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $126.63 million, representing a 15.5% year-over-year growth, which highlights the company's robust growth in the market and sustained customer demand, potentially boosting investor confidence.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, showcasing the company's strong performance in revenue generation, which may attract more investor interest.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with two downward adjustments, while revenue estimates saw one upward revision and two downward adjustments, indicating a cautious market sentiment regarding the company's future performance, which could impact short-term stock price volatility.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Phreesia Stock Plummets After Mixed Q4 Earnings Report
- Earnings Report Disappointment: Phreesia's Q4 2026 earnings report revealed a revenue of $127.1 million, surpassing expectations, yet the earnings per share of $0.02 fell significantly short of the anticipated $0.06, resulting in a 27.5% stock drop in early trading.
- Sales Growth Highlight: Despite the earnings miss, Phreesia achieved a 16% year-over-year sales increase and reported profitability for both the quarter and the full year at $0.04 per share, indicating some resilience in the market.
- Free Cash Flow Performance: The company generated a positive free cash flow of $28.5 million for the quarter and $54.4 million for the year, reflecting a solid cash position after accounting for capital expenditures and software costs, despite the earnings challenges.
- Cautious Future Outlook: Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million from a previous range of $545 million to $559 million, highlighting uncertainty regarding spending commitments from pharmaceutical clients, although it still anticipates a 7% growth.
See More
PHREESIA Q4 ADJUSTED EBITDA REACHES USD 29.4 MILLION, BEATING IBES ESTIMATE OF USD 28.1 MILLION
Financial Comparison: PHREESIA reported a Q4 adjusted EBITDA of USD 29.4 million, indicating strong financial performance.
Industry Benchmark: In contrast, the estimate for IBESE's adjusted EBITDA stands at USD 28.1 million, highlighting a competitive landscape.
See More
PHREESIA REPORTS Q4 NET INCOME OF USD 1.295 MILLION
- Company Overview: PHR EESIA reported a net income of USD 1.295 million for Q4.
- Financial Performance: The financial results indicate a positive performance in the fourth quarter.
See More
PHREESIA REPORTS RESULTS FOR FOURTH QUARTER OF FISCAL YEAR 2026
- Fiscal Results Announcement: PHR EESIA has announced its fiscal results for the fourth quarter of 2026.
- Performance Overview: The results provide insights into the financial performance and economic standing of the organization during this period.
See More
Phreesia Set to Announce Q4 Earnings on March 30
- Earnings Announcement Schedule: Phreesia (PHR) is set to announce its Q4 earnings on March 30 after market close, with a consensus EPS estimate of $0.32, reflecting a substantial year-over-year increase of 390.9%, indicating a significant improvement in the company's profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $126.63 million, representing a 15.5% year-over-year growth, which highlights the company's robust growth in the market and sustained customer demand, potentially boosting investor confidence.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, showcasing the company's strong performance in revenue generation, which may attract more investor interest.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with two downward adjustments, while revenue estimates saw one upward revision and two downward adjustments, indicating a cautious market sentiment regarding the company's future performance, which could impact short-term stock price volatility.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Phreesia Stock Plummets After Mixed Q4 Earnings Report
- Earnings Report Disappointment: Phreesia's Q4 2026 earnings report revealed a revenue of $127.1 million, surpassing expectations, yet the earnings per share of $0.02 fell significantly short of the anticipated $0.06, resulting in a 27.5% stock drop in early trading.
- Sales Growth Highlight: Despite the earnings miss, Phreesia achieved a 16% year-over-year sales increase and reported profitability for both the quarter and the full year at $0.04 per share, indicating some resilience in the market.
- Free Cash Flow Performance: The company generated a positive free cash flow of $28.5 million for the quarter and $54.4 million for the year, reflecting a solid cash position after accounting for capital expenditures and software costs, despite the earnings challenges.
- Cautious Future Outlook: Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million from a previous range of $545 million to $559 million, highlighting uncertainty regarding spending commitments from pharmaceutical clients, although it still anticipates a 7% growth.
See More
